All stock lists
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
US · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - Specialty & Generic
4.95+0.60 (+13.79%)
Market cap
$74.2M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 11, 2009
Website
Insider Score
––Not scored
CPIX Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From CPIX’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $31.3M
- Net income
- -$10.6M
- Net margin
- -33.9%
Leverage17 / 20
Little or no net debt.
- Total debt
- $4.7M
- Cash
- $3.9M
- Debt / equity
- 0.27
Liquidity6 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $33.6M
- Current liabilities
- $35.2M
- Current ratio
- 0.96
Cash generation9 / 20
Roughly cash-neutral.
- Operating cash flow
- $746K
- Free cash flow
- -$1.1M
- FCF margin
- -3.6%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 15.0M
- Share growth (1y)
- 0.1%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
CPIX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 166.46 K | 9.13 M | 13.68 M | 8.29 M | 10.84 M | 11.71 M |
| Revenue Growth (YoY) | -98.46 % | -22.04 % | 31.08 % | -8.73 % | 10.04 % | 37.84 % |
| Cost of Revenue | 37.40 K | 1.93 M | 2.24 M | 988.76 K | 2.01 M | 1.43 M |
| Gross Profit | 129.05 K | 7.20 M | 11.44 M | 7.30 M | 8.83 M | 10.29 M |
| SG&A Expense | 2.55 M | 7.62 M | 10.25 M | 7.01 M | 7.10 M | 6.69 M |
| R&D Expense | 772.16 K | 1.46 M | 1.55 M | 1.25 M | 1.47 M | 1.30 M |
| Operating Expenses | 3.29 M | 10.33 M | 12.81 M | 9.27 M | 9.57 M | 9.00 M |
| Operating Income | -3.16 M | -3.13 M | -1.37 M | -1.97 M | -747.48 K | 1.29 M |
| Pretax Income | -3.10 M | -3.14 M | -1.41 M | -1.94 M | -729.54 K | 1.25 M |
| Tax Provision | 3.87 K | 3.87 K | 23.25 K | 5.67 K | 5.67 K | 5.67 K |
| Net Income | -4.12 M | -3.14 M | -1.41 M | -1.94 M | -740.74 K | 1.26 M |
| EPS (Basic) | -0.27 | -0.22 | -0.09 | -0.13 | -0.05 | 0.08 |
| EPS (Diluted) | -0.27 | -0.22 | -0.09 | -0.13 | -0.05 | 0.08 |
| Shares Outstanding | 14.98 M | 14.96 M | 14.96 M | 14.95 M | 14.96 M | 14.94 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.